Over a decade of randomized controlled trial data demonstrates excellent outcomes with transcatheter or surgical aortic valve replacement (TAVR or SAVR) for patients with symptomatic severe aortic stenosis (AS) regardless of surgical risk. The 2020 American College of Cardiology/American Heart Association guidelines recommend both options for low-risk AS patients aged 65 to 80. However, the fastest growing population of patients receiving TAVR in the US is <65 years old, with little data to support the practice. The American College of Cardiology’s Cardiac Surgery Team Section Leadership and Interventional Cardiology Councils, a multidisciplinary collaboration of cardiologists and cardiac surgeons, sought to summarize the relevant data into a decision-making tool for heart valve teams. A literature review was completed, and guidelines, randomized controlled trials, and large observational studies were summarized into a pragmatic decision-making approach to treating young and low-risk patients with AS.

Editors

JACC: Cardiovascular Interventions Editor-in-Chief
David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC Editor
Michael C. McDaniel, MD

Authors

Tanush Gupta, MD

Kendra J. Grubb, MD, MHA

Important Dates

Date of Release: November 11, 2024
Term of Approval/Date of CME/MOC Expiration: November 10, 2025